Quantum-Si Incorporated announced its financial results for the second quarter ended June 30, 2025, reporting revenue of $591,000. The gross profit for the quarter was $351,000, with a gross margin of 59%.
Total operating expenses for Q2 2025 were $30.5 million, including a $3.362 million net expense related to a preliminary legal settlement. Adjusted operating expenses were $23.8 million. The net loss for the quarter was $28.8 million, and adjusted EBITDA was negative $22.2 million.
As of June 30, 2025, the company held $214.2 million in cash, cash equivalents, and marketable securities. Following a $50 million registered direct offering that closed on July 8, 2025, Quantum-Si now believes it has sufficient capital to carry operations into the second quarter of 2028.
Management noted experiencing the full effect of NIH funding challenges, which slowed capital sales, but observed consistent demand for consumables. In response, the company launched expanded instrument acquisition options, including reagent rentals, to grow its user base and capture consumable revenue.
On the development front, the Version 4 Sequencing Kit remains on track for a Q3 2025 launch, and the Version 3 Library Preparation Kit is slated for a Q4 2025 launch. The company also remains on track to achieve successful protein sequencing on a prototype Proteus system by the end of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.